In 2017, the FDA granted "Breakthrough Therapy" Designation to MDMA for the treatment of post-traumatic stress disorder (PTSD) and is currently in phase 3 clinical trials. Popularly known as a recreational drug, and as the main ingredient in ecstasy, MDMA is paving the way for the possible near-term legalization of psychedelic therapy.

On this episode, we talk to Anne Wagner, a clinical psychologist and one of the lead investigators involved in the clinical trials of MDMA + cognitive-based psychotherapy for PTSD. Anne tells us how she ended up working in the cutting edge of psychedelic science and what these studies offer for the future of mental health. In her clinical practice, Anne applies a cognitive-behavioural and mindfulness-based approach to therapy and she also offers preparation and integration of psychedelic and non-ordinary state experiences. We got to connect with Anne at her new clinic, Remedy in Toronto.

Poem by Thal Mohammed

Music by Hoiking Fung

https://youtu.be/HzN6E8BJUQw

Shownotes

http://www.soulspacepodcast.com/2019/05/05/episode15/